Aspire Biopharma Holdings (ASBP) Non Operating Income (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Non Operating Income of -$1.6 million for Q1 2026, down 309.7% year-over-year from $751893.9 in Q1 2025, and up 44.84% quarter-over-quarter from -$2.9 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Non Operating Income (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Non Operating Income for 5 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 309.7% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$6.3 million (down 3435.18% YoY), while the FY2025 annual figure was -$5.1 million, down 5134.88% from the prior year.
- Non Operating Income climbed to -$1.6 million in Q1 2026 per ASBP's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.2 million in Q1 2023 and bottomed at -$2.9 million in Q4 2025.
- Historically, Non Operating Income has averaged $224592.1 across 5 years, with a median of $55577.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 14844.13% — and 2025, when it slumped 1066.86%.
- Aspire Biopharma Holdings' Non Operating Income stood at $2.5 million in 2022, then plunged by 90.11% to $251702.0 in 2023, then sank by 140.22% to -$101246.0 in 2024, then slumped by 2723.13% to -$2.9 million in 2025, then surged by 44.84% to -$1.6 million in 2026.
- Business Quant data shows ASBP's Non Operating Income at -$1.6 million in Q1 2026, -$2.9 million in Q4 2025, and -$704996.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | -1.58 Mn |
| Dec 31, 2025 | -2.86 Mn |
| Sep 30, 2025 | -704,996.00 |
| Jun 30, 2025 | -1.18 Mn |
| Mar 31, 2025 | -384,848.00 |
| Jun 30, 2024 | -101,246.00 |
| Mar 31, 2024 | 55,577.00 |
| Dec 31, 2023 | 251,702.00 |
| Sep 30, 2023 | 255,484.00 |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Dec 31, 2022 | 2.54 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 418,533.00 |
| Mar 31, 2022 | 21,393.00 |